Malignant hypertension. A clinical follow-up study with special reference to renal and cardiovascular function and immunogenetic factors.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006680:HLA Antigens / Q000032:analysis; D006439:Hemodynamics; D006801:Humans; D006974:Hypertension, Malignant / Q000276:immunology / Q000503:physiopathology*; D007668:Kidney / Q000503:physiopathology*; D007962:Leukocytes / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D010991:Plethysmography; D011379:Prognosis; D012189:Retrospective Studies; D014655:Vascular Resistance / Q000187:drug effects
D000959:Antihypertensive Agents; D006680:HLA Antigens